Jeremy Chrisp – CEO 

Jeremy is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD). He has more than 30 years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.

Dr David Fuller – Acting CMO

David is a pharmaceutical physician with extensive experience in the clinical development, regulatory approval and commercialization of new therapeutic products. He specialises in the early stage development of oncology therapeutics and has more than 30 years international experience in the pharma/biotech sector for companies including Roche, Pfizer, Orphan Medical (US), Genzyme (Holland and UK), Arana Therapeutics and, more recently, Syneos Health (CRO). He has directly led four product approvals through the US FDA and EMA. David holds dual qualifications in Medicine and Pharmacy from the University of Sydney.

Derek Bolling – CFO 

Derek is a highly competent financial and accounting executive, gained from listed and unlisted companies and from high net wealth individuals. This includes engagements with higher education institutions, creative agencies, renewable energy technology providers and biotech start-ups. His experience in the Australian healthcare market includes working with companies such as Medsaic, Medical Therapies (now Cellmid), CathRx and Immune System Therapeutics.


Jeanette Wood – Scientific Advisor

Jeanette is drug discovery expert with a PhD in Pharmacology from the University of Otago, Dunedin. Her early research focused on innovative small molecule drugs targeting the renin-angiotensin system and later, at Novartis, on therapies for cancer and inflammatory diseases. In both the cardiovascular and cancer areas, Jeanette successfully led various global drug discovery teams and research groups and she played a role in the discovery and/or profiling of several marketed drugs and compounds in the Novartis development portfolio.

Under her leadership at AstraZeneca, AZ9291 (Tagrisso), was selected for development and has recently been registered for the treatment of lung cancer patients with the EGFR resistance mutation, T790M. GKT771, a selective NOX1 inhibitor, was discovered and selected for development under her leadership in Genkyotex.

She has served as a Scientific and Strategic Advisor to numerous biotech companies and universities with drug discovery activities around the world.
Jeanette has also been an invited speaker at numerous scientific and career mentoring events and served as a part time lecturer at Departments of Pharmacy/Pharmacology in New Zealand, Switzerland, Korea and Singapore. She has been awarded several prizes for her scientific and drug discovery
excellence and is author of numerous patents and publications.

Pamela Munster – Scientific Adviser

Professor Munster is a Professor of Medicine at the University of California San Francisco, where she is leader of the Developmental Therapeutics Program/Helen Diller Family Comprehensive Cancer Center, Director of The Early Phase Clinical Trials Unit, and coleader of the Center for BRCA Research. In addition to her laboratory research, she is an oncologist whose focus is on epigenetics and developing novel strategies to treat patients with incurable cancers. She serves on multiple local, national, and international committees focused on developing new treatments for cancer. She has authored textbooks and is a frequent lecturer. A native of Switzerland, she leads breast awareness campaigns in the US, UAE, and India. Pamela holds a M.D. from the University of Bern, Switzerland.

Professor Alfredo Budillon, MD, PhD

Alfredo is an oncologist and an expert in experimental anticancer therapeutics and epigenetics. He is a Professor at the Comprehensive Cancer Center Istituto Nazionale dei Tumori G. Pascale of Napoli, Italy, where he is their Director of Experimental Pharmacology Unit. Professor Budillon is also the Director of the Proteomics and Metabolomics Programs at the Mercogliano Research Center, the high-technology facility branch of Institute Pascale.

Alfredo is author of more than 170 publications, most on the molecular mechanism of novel anticancer drugs, particularly epigenetic drugs, and the potential combination approaches with conventional drugs. Some of these findings were translated into clinical trials particularly in rectal and colon cancer patients. Recently he focused his research on targeting metabolic reprogramming in cancer cells, particularly in cancer stem cell compartment. Other scientific interests are related with System Biology approach and identification/validation of circulating prognostic/predictive biomarkers in liquid biopsies (i.e metabolites, EVs, Immune cell subpopulations).

Currently Alfredo is the Co-Chair of “Small Molecules” Platform at the European Infrastructure for Translational Medicine (EATRIS) and Member of the Board of A-IATRIS, the Italian Node of EATRIS.

Professor Roberto Pili, MD

Roberto’s research and practice interests include epigenetics, genitourinary cancer and nutritional treatment of cancer patients. He is Professor of Medicine, Chief of the Division of Hematology/Oncology and Associate Dean for Cancer Research in the Jacobs School of Medicine and Biomedical Sciences at University at Buffalo. He also holds a secondary appointment in the Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions. Additionally, Professor Pili is vice president for oncology services within Great Lakes Cancer Care Collaborative, a consortium of eight organisations including UBMD, Erie County Medical Center and Kaleida Health.

Roberto is a graduate of the Catholic University School of Medicine in Rome, Italy where he completed training in internal medicine, followed by an internal medicine residency at Montefiore Medical Center at the Albert Einstein College of Medicine in New York. Professor Pili did his postdoctoral fellowship in biological chemistry at the National Institutes of Health and a clinical-research fellowship in medical oncology at Johns Hopkins.